Table 4.
454 samples | PID | 454 APD without correction | 454 APD corrected from double mutations | APD from MID2 (control) | 454 APD corrected from control | SGS APD |
---|---|---|---|---|---|---|
MID22 | 1 | 0.0100 | 0.0082 | 0.0016 | 0.0066 | 0.0043 |
MID23 | 2 | 0.0184 | 0.0167 | 0.0016 | 0.0151 | 0.0107 |
MID24 | 3 | 0.0098 | 0.0097 | 0.0016 | 0.0081 | 0.0057 |
MID25 | 4 | 0.0248 | 0.0225 | 0.0016 | 0.0209 | 0.0183 |
MID26 | 5 | 0.0127 | 0.0125 | 0.0016 | 0.0109 | 0.0111 |
MID28 | 6 | 0.0061 | 0.0038 | 0.0016 | 0.0022 | 0.0014 |
MID29 | 7 | 0.0160 | 0.0150 | 0.0016 | 0.0134 | 0.0094 |
MID30 | 8 | 0.0085 | 0.0068 | 0.0016 | 0.0052 | 0.0038 |
MID31 | 9 | 0.0179 | 0.0165 | 0.0016 | 0.0149 | 0.0120 |
Patient 454 sequences and MID2 control sequences were aligned with HIV-1 subtype B consensus sequence.
Welch’s T test, two-tailed between 454 APD without correction and SGS APD, p = 0.064; between 454 APD corrected for background and SGS APD, p = 0.400.